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1. Introduction
Cancer is the third most lethal disease in the world after cardiovascular, parasitic and infectious
diseases, based on reports from American Cancer Society (ACS) [1,2]. In 2011, nearly 13 million
people are diagnosed with cancer and hence, cancer continues to be a great threat to people
now [3]. Thus, the medical needs for cancer remain one of the most demanding areas in
scientific research. Several studies have been carried out to prevent and treat cancers. Che‐
moprevention is defined as pharmacological intervention with synthetic or naturally occurring
compounds that may inhibit or prevent carcinogenesis [4]. Cancer treatment involves surgery,
radiation and drugs. Surgery-the first line of therapy, is used for early stage of cancer.
Radiotherapy is most often applied in a localised setting and conjunction with surgical
procedures. The last one, drugs are implemented with chemotherapy (CTX), which employs
a wide group of drugs that have cytotoxic effects. The anticancer drugs inhibit cell division
and proliferation and are less selectivity towards cancer cells. Thus, these drugs not only
destroy cancer cells but also destroy normal cells.
In this chapter “Anti Cancer Drug: Friend or Foe” we have evaluated the beneficial and harmful
effects of anticancer drugs.
2. Anticancer drugs — Benefical effects
Anticancer or chemotherapy drugs are chemicals that can denature cancer cells by arresting
their growth. Though anticancer drugs affect dividing cancer cells, normal cells are also
affected in the course of the event. The most affected cells are:
• bone marrow,
• gonads (sex organs),
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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• gastrointestinal tract, and
• skin (hair follicle cells).
In addition to the above organs, liver and kidneys (slow proliferating cells) are affected since
they are the organs of metabolism or target organs of toxicity.
Today, more than 100 different drugs have been used for chemotherapy, either alone or in
combination with other treatments. For several years, the most effective drugs used in
chemotherapy were considered to be DNA damaging agents [5]. These drugs can be divided
into different categories based on their mechanism of action. They are summarized in Figure 1.
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Figure 1. Classification of anticancer drugs.
2.1. Alkylating agents (Figure 2)
This class of drugs directly damages DNA by adding methyl or other alkyl groups onto
nucleotide bases [6] and thereby inhibit their correct utilization by base pairing leading to
mutation, DNA fragmentation as well as inhibition of DNA replication and transcription. They
also disrupt cell respiration and intermediary metabolism by alkylation of proteins and
enzymes. The anticancer drugs that contain alkylating agents are cyclophosphamide, ifosfamide,
melphalan, and chlorambucil.
2.2. Anti-metabolites (Figure 3)
Inhibitors of DNA synthesis inhibit essential biosynthetic processes or are incorporated into
DNA, RNA, proteins and other macromolecules. These drugs (Figure 3) are either structural
analogues for heterocyclic bases or agents interfering with folate metabolism. DNA building
blocks include heterocyclic bases and folic acid. They inhibit main steps in the formation of
purine and pyrimidine bases as well as nucleotides [7]. This class of drugs includes antifolates
(methotrexate, pemetrexed) [8], antipyrimidines (5-fluorouracil, capecitabine, eniluracile, hydroxyur‐
ea) [9] and antipurines (6-mercaptopurine, 6-thioguanine).
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Figure 3. Anti-metabolites.
2.3. Antitumor Antibiotics and Topoisomerase Inhibitors
Antitumor antibiotics and topoisomerase inhibitors are obtained from the cultures of various
microorganisms. Examples:
• Doxorubicin (Adriblastina),
• Daunorubicin (Remember Cerubi),
• Bleomycin (Bleoc's),
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Figure 2. Family of alkylating agents.
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• Mitomycin,
• Mithramycin,and
• Epirubicin.
Furthermore, topoisomerase inhibitors have been used to interfere with the action of topoiso‐
merase I and II enzymes. These enzymes regulate the changes in DNA structure which includes
DNA replication, transcription, recombination, and chromatin remodelling [10-15]. The
important inhibitors are camptothecin, irinotecan, topotecan for Topoisomerase I; Etoposide
(VP-16), teniposide, doxorubicin, daunorubicin, ellipticine etc, for Topoisomerase II. These drugs
inhibit the ability of the topoisomerase to cleave nucleic acid molecules. Although these types
of drugs have important clinical efficacy, they have undesired and/or adverse effects such as
drug resistance, poor bioavailability problems and myelosuppression. Furthermore, some of
them lead to disruption or stabilization of DNA, so that these are also called as topoisomerase
poisons. The other inhibitors of topoisomerase bind to enzyme or DNA and interrupt the
catalytic activity of the enzyme and prevent the enzyme binding actions.
Figure 4. Structure of DNA-Topoisomerase II.
Bi-and ter-benzimidazole derivatives constitute a new class of DNA Topo I and II inhibitors
[16-20]. In addition, a camptothecin derivative with a benzoxazole ring is shown significantly
more potent than camptothecin as an inhibitor of DNA Topo I [21]. It is of the opinion that a
fused ring system in the chemical structure is critical and important for the biological activity.
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For example, 2-(4-aminophenyl)benzothiazoles, are observed by Shi et al. [22], exhibit potent
anti-tumour activity against some cell lines (breast, ovarian, colon, and renal cell lines). Choi
et al. [23] also synthesized a series of 2-(4-aminophenyl)benzothiazole and evaluated the Topo
II inhibitory activity.
There are studies on the inhibitory effects of some novel fused heterocyclic compounds,
(benzimidazole, benzoxazole, benzothiazole, and oxazole(4,5-b)pyridine derivatives) on eukaryotic
DNA Topo II (Figure 4) in a cell-free system [24-26]. These compounds displayed more potent
inhibitory activities than the reference drug etoposide (Table 1, Figure 5) [17-20]. Molecular
modeling of the possible structural motifs of the fused heterocyclic compounds given in Table
1 have been studied to expose their binding mode to eukaryotic DNA topoisomerase II by
molecular docking studies. The interactions involved in the anti-tumour activities of fused
heterocyclic compounds lead to the rational design of novel eukaryotic DNA topoisomerase
II-targeted drugs [27,28].
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Figure 5. The structure of the reference drug-etoposide.
Compound R R1 R2 R3 Z IC50 (µM)a
1a* H NO2 OCH3 H CH 17
1b H CH3 F H CH 433.2
1c* H CH3 NO2 H CH 18.8
1d NH2 H H C2H5 CH 115.5
1e CH3 H CH3 CH3 CH 44.4
1f Cl H H C2H5 CH NE
1g CH3 H OCH3 H CH 433.0
1h NO2 H H H CH 32.4
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1i Cl H H Cl CH NE
1j CH3 H H NHCH3 CH 128.4
1k* NO2 H H OC2H5 CH 22.4
1l H H H C2H5 N 45.6
1m H H H Cl N 119.5
1n H H H C(CH3)3 N 108.3
1p H H H CH3 N 91.2
Compound R R1 X IC50 (µM)a
2a NO2 Br O NE
2b H OCH3 O 86.6
2c CH3 NO2 NH NE
2d CH3 CH3 NH 101.9
2e CH3 NH2 NH 46.8
Compound R R1 X Y IC50 (µM)a
3a H Cl S O NE
3b* CH3 H NH S 27.4
3c* COOCH3 H NH S 17
3d H H NH CH2 NE
3e* NO2 H NH O 24.8
3f* H H S O 11.4
Compound R R1 IC50 (µM)a
4a* H 24.1
4b
rH2C
C2H5 315.1
4c
H2C
F 206.9
4d O2H2C H 420.1
4e
2C
F 420.1
Etoposide 21.8
Table 1. Eukaryotic DNA topoisomerase II inhibitory activities of novel 2,5,6-substituted benzoxazole, benzimidazole
and benzothiazole(4,5-b)pyridine derivatives. [The asterisk (*) refers to structures that are effective, according to the
reference drug, etoposide. The small letter (a) implies that eukaryotic DNA topoisomerase II-50% inhibitory activity of
the tested compounds and the reference drug, etoposide at the micromolar (µM) concentration of IC50 values. NE: not
effected].
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2.4. Herbal remedies
These drugs show their effects on mitosis during metaphase by preventing the formation of the spindle.
Etoposide VP-16 (Vepesid), an effective anticancer drug, is applied to treat a broad spectrum of
human cancers for more than two decades. Unfortunately, its wide therapeutic application is
often hindered by multidrug resistance (MDR), low water solubility and toxicity. New
derivatives of benzoxazoles, benzimidazoles and related fused heterocyclic compounds,
exhibited significant eukaryotic DNA topoisomerase II inhibitory activity, were synthesized
and exhibited better inhibitory activity even compared with the drug etoposide (Figure 5) [27].
Other examples are:
• Vinblastine(Velber A),
• Vincristine(Oncovin),
• Podophyllotoxin,
• Teniposide(VM26-Bristol),and
• Vindesin(Eldisine).
2.5. Hormones and hormone antagonists
Hormone antagonists are used for tumors caused by hormones or hormonal imbalance.
Examples:
• Glucocorticoidhormones and
• Estrogens.
The endogenous estrogens in women are steroid hormones. Possible consequences of the lack
of estrogen in postmenopausal women are frequently reported, including postmenopausal
symptoms, increased risks of osteoporosis, coronary heart disease and Alzheimer's disease
[29-33]. On the other hand, the cumulative exposure to estrogen encourages development of
female reproductive cancers. Such examples include breast cancer and uterus cancer, which
are found associated with hormone replacement therapy, early menarche and late menopause
[34]. The contribution of estrogens in various physiological and pathological pathways
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depends on the binding to estrogen receptors. It also activates transcription of estrogen
responsive genes [35-38].
The anti-cancer drug benzodihydro [α]carbazole (BDHC), which is widely used to treat breast
cancer, and for which the primary target is the human estrogen receptor (hER) [39]. This study
reveals a brief introduction of BDHC therapy for breast cancer and the related mechanistic
pictures of small compounds signaling through hER by using QSAR and docking methods.
They were applied to understand the nature of 5,6-dihydro11-alkylbenzo [α]carbazole
derivatives (Table 2) and to investigate the interactions of homolog series with binding sites
on selected a-chains of human estrogen receptors (hER).
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Table 2. Relative Binding Activities (RBA) of 11-Alkyl–6,11-dihydrohydroxy-5H-benzo [α]carbazoles [39].
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Furthermore, the X-ray structure of 17β-estradiol in hER was superimposed on compound 2
and 3 on the docked structure (Figure 6).
 
Figure 6. Estradiol (green) superimposed on compound 2 and 3 in the a-chain’s binding site of hER. Key residues and
H-bonds are shown by yellow lines and blue dotted lines.
Other hormonal antagonists are:
• Progestins,
• GnRH (gonadotropin releasing hormone), and
• Antiandrogens.
2.6. Other medicines
Medicines that are used as anticancer drugs are:
• Platinum-based drugs (cisplatin, carboplatin),
• L-Asparaginase (Crasnit's),
• Hydroxyurea (Hydrea), and
• Amsacrine (Amsidyl).
Many of the CTX drugs that are employed are naturally occurring compounds extracted from
plants, while others are synthetic. Genotoxic agents bind to DNA and directly and/or indirectly
affect the replication which induces the apoptosis. These agents are also divided into three
important subunits-alkylating agents, intercalating agents and enzyme inhibitors. Etoposide
is an enzyme inhibitor which inhibits topoisomerase II and prevents resealing of DNA that
leads to cell death. However, this drug structure exhibits undesired effect for treatment of the
disease. Due to this reason, different methods have been improved to evaluate the adverse
effects of etoposide, the most effective and potent drug.
There are two approaches to evaluate the adverse effects of the potent drugs-first one, is
synthetic way. Researchers try to find derivatives of this drug agent with the conventional
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way. In the another approach, they use novel and rational drug design, discovery and
development methods which are more economic and minimize time and labor by using
computer models, compared with the usual conventional methods.
3. Harmful (or toxic) effects of anticancer drugs
An understanding of toxicity or adverse effects of anticancer compounds is important to design
effective and potent drug combinations and also to interpret toxicological profile of new
chemical entities. Most cytotoxic anticancer agents are evaluated at the maximum tolerated
dose levels. The toxicity of these compounds is often a manifestation of their mechanism of
action and their effect on growing normal cells such as hair follicle cells, gastrointestinal surface
epithelial cells, and stem cells.
Toxicity or adverse effects of anticancer drugs include the following:
• Bone marrow depression due to damage for the growing stem cells causes a reduction
in the white blood cell, platelet, and red cell counts. These, in turn, could cause suscept‐
ibility  to  infections,  excessive  bleeding,  and  anemia.  In  addition,  certain  drugs  cause
unique and severe bone damage, such as the osteonecrosis of the jaw associated with
bisphosphonates [40].
• Damage to growing cells may cause temporary loss of hair (alopecia), skin rashes, changes
in the color and texture, or loss of fingernails and toenails. These toxicities are usually
reversible.
• Surface epithelial damage to the gastrointestinal tract may result in ulcers, stomatitis,
difficulty in swallowing (dysphagia), vulnerability to oral infections such as candidiasis,
and changes in saliva secretion. In addition, nausea, vomiting, diarrhea, or constipation
occur commonly.
• Some drugs may cause kidney damage due to extensive cell destruction, purine catabolism,
and deposition of urates in the renal tubules. The activity of drugs depends on the individual
physiological system and the mode of renal handling of drugs.
• Cinnamaldehyde (an anticancer drug) at a dose level of 73.5 mg / kg body weight / day
induced histopathological changes of kidney accompanied by increased activity of marker
enzymes and an imbalance in the antioxidant status, in rats. Cinnamaldehyde induced renal
damage, is due to the reactive oxygen species that formed while in the free radical scav‐
enging reactions [41-43].
• In addition, liver damage may occur due to large blood supply. Metabolic conditions of the
liver and the kidney are usually monitored for possible correlation to drug levels in the
blood and dosage adjustments, since these are the major drug elimination sites or the target
organs of toxicity.
• Certain symptoms and adverse effects associated with cancer could be secondary to disease
progression. For example, cancer metastases to the bones could cause chronic pain due to
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the proliferation of cancer cells in the bones and the associated bone remodeling and
destruction. Also, tumors that compress veins, the use of central vein catheter, and relative
immobility of the patient could lead to deep vein thrombosis with potential pulmonary
embolism [44-46].
• Drugs such as paclitaxel and vincristine could cause peripheral neuropathy. Similarly,
anthracyclines are known for rare but severe cardiotoxicity [47-49].
Thus, adverse effect and dose-limiting toxicity of anticancer compounds could be a manifes‐
tation of either their mechanisms of action or unrelated toxicities common to a given chemical
entity of compounds (anthracyclines and etoposide). A close attention to monitor the emer‐
gence of known side effects of anticancer drugs, as well as those observed in the preclinical
animal toxicology studies, ensures patient safety in early oncology drug clinical trials.
4. Conclusions and perspectives
Especially, chemotherapy has been integrated into treatment programs with surgery and
radiation therapy. The major problem of the clinical efficacy in chemotherapy is because of
toxicity of the anticancer drugs to the normal tissues of the body. Rapidly proliferating tissues
such as bone marrow, gastrointestinal tract, hair follicle, etc are the major sites of acute
toxicities. In addition, chronic and cumulative toxicities may also occur. There are measures
and agents which can improve the toxicities of anticancer drugs. Furthermore, current
challenges of anticancer drug development include the significant time and cost involvement,
and the low success rates. These issues lead to increasing efforts of the pharmaceutical industry
toward increasing the effectiveness of the drug discovery and development process to
minimize failure of drug candidates at later stages of development. It also includes develop‐
ment of high throughput preclinical screening methods (computational molecular modeling
techniques) and biological assays with greater specificity and predictability.
Increasing emphasis is being placed on developing a mechanistic understanding of the
physicochemical and biological phenomena involved in drug development such as chemical
structure and polymorph stability, and pharmacokinetics. The use of mathematical models to
explain the mechanisms of drug degradation and predict the outcomes of formulation and
process changes and scale-up is increasingly being adopted such as Quantitative Structure
Activity Relationships (QSAR). This chapter summarises the beneficial and harmful (toxicity)
effects of anticancer drugs and other measures adopted for its management. Proper handling
of anticancer agents is the utmost importance at the earlier phase because it has an affiliation
with the course of treatment and outcome of the patient in his physical, mental and social
wellbeing. Because of these reasons, computer aided drug design and discovery are used to
reduce the side effects of the anticancer drugs. These procedures result in effective therapeutic
options for chemotherapy.
On general consideration, antioxidants (vitamins) play a significant role to ameliorate the
toxicity. Thus, fruits and vegetables in the diet might protect human health from toxic effects
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of drugs at certain extent [50]. While in chemotherapy, if the patients are given vitamin rich
food (vegetables, fruits, etc), then toxicity of the chemotherapeutic drugs can be prevented at
certain extent.
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